Patents by Inventor Xin W. Wang

Xin W. Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF MiR-26 FAMILY AS A PREDICTIVE MARKER FOR HEPATOCELLULAR CARCINOMA AND RESPONSIVENESS TO THERAPY
    Publication number: 20150329919
    Abstract: Provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-? therapy, by detecting the level of microRNA-26 expression in a sample obtained from the patient.
    Type: Application
    Filed: August 4, 2015
    Publication date: November 19, 2015
    Applicants: THE OHIO STATE UNIVERSITY, FUDAN UNIVERSITY, The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Xin W. Wang, Junfang Ji, Carlo M. Croce, Hui-Chuan Sun, Zhao-You Tang
  • Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
    Patent number: 9125923
    Abstract: It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-? therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-? therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: September 8, 2015
    Assignees: The Ohio State University, Fudan University, The United States of America as Represented by the Secretary of the Dept. of Health and Human Services
    Inventors: Xin W. Wang, Junfang Ji, Carlo M. Croce, Hui-chuan Sun, Zhao-you Tang
  • MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma
    Publication number: 20120329672
    Abstract: Provided herein are microarrays, kits, methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 27, 2012
    Inventors: Carlo M. Croce, Xin W. Wang, Anuradha Budhu, Zhao-you Tang
  • MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
    Patent number: 8252538
    Abstract: Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: August 28, 2012
    Assignees: The Ohio State University, The United States of America as represented by the Secretary of the Department of Health and Human Services National Institute of Health, Office of Technology Transfer, Liver Cancer Institute and Zhongshan Hospital, Fudan University
    Inventors: Carlo M. Croce, Xin W. Wang, Anuradha Budhu, Zhao-you Tang
  • Use of MiR-26 Family as a Predictive Marker for Hepatocellular Carcinoma and Responsiveness to Therapy
    Publication number: 20110124521
    Abstract: It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-? therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-? therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided.
    Type: Application
    Filed: June 11, 2009
    Publication date: May 26, 2011
    Applicants: THE OHIO STATE UNIVERSITY, FUDAN UNIVERSITY, OF HEALTH AND HUMAN SERVICES
    Inventors: Xin W. Wang, Junfang Ji, Carlo M. Croce, Hui-Chuan Sun, Zhao-you Tang
  • MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma
    Publication number: 20100120898
    Abstract: Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.
    Type: Application
    Filed: November 1, 2007
    Publication date: May 13, 2010
    Applicants: The Ohio State University Research Foundation, Department of Health and Human Services
    Inventors: Carlo M. Croce, Xin W. Wang, Anuradha Budhu, Zhao-you Tang